Suppression by platelet factor 4 of the myogenic activity of basic fibroblast growth factor.
The effect of platelet factor 4 (PF4) on myoblast cultures with or without basic fibroblast growth factor (bFGF) or other growth factors was investigated in the present in vitro experiments, with reference to bFGF binding to myoblast membrane fraction. When PF4 was added to the culture medium 1 day after myoblast cultivation, the nuclei of both myoblasts and myotubes were markedly reduced in number in a dose-dependent manner, whereas the inhibitory effect of PF4 on myoblast development was not observed when PF4 was added to the culture medium 3, 7, or 14 days after myoblast cultivation. In contrast, bFGF significantly increased the numbers of myoblast and myotube nuclei. When bFGF and PF4 were simultaneously added to the culture medium, PF4 abolished the facilitatory effects of bFGF on myogenesis. The real-time biospecific interaction analysis (BLA) core system showed that the myoblast membrane fraction at 1 day after cultivation contains bFGF-binding elements which are blocked by PF4 in a dose-dependent manner. Moreover, [126I]-bFGF binding experiments indicated the existence of both high and low affinity binding sites on myoblast membranes, although the high affinity binding sites decreased in number and the dissociation constant increased in value as the culture period was prolonged. Among the six other growth factors examined, acidic fibroblast growth factor and platelet-derived growth factor-BB stimulated myogenesis, and their effects were blocked by PF4 treatment. These findings suggest that: 1) PF4 inhibits myoblast proliferation and myotube formation only for a limited initial period of cultivation, possibly because of the time-dependent down-regulation of high affinity bFGF receptors: and 2) PF4 may be used as a tool to investigate the function of endogenous heparin-binding growth factors upregulated transiently at a certain developmental stage or in case of tissue damage and repair, even though it is not monospecific to bFGF.
Peng
H
H
Department of Anatomy and Physiology, Ehime University School of Medicine, Japan.
Wen
T C
TC
Igase
K
K
Tanaka
J
J
Matsuda
S
S
Aburaya
J
J
Sakanaka
M
M
D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D002642:Chick Embryo; D004305:Dose-Response Relationship, Drug; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006133:Growth Substances / Q000494:pharmacology; D008854:Microscopy, Electron; D009132:Muscles / Q000187:drug effects* / Q000648:ultrastructure; D010978:Platelet Factor 4 / Q000378:metabolism / Q000494:pharmacology*; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism; D013997:Time Factors
D006133:Growth Substances; D017468:Receptors, Fibroblast Growth Factor; D016222:Fibroblast Growth Factor 2; D010978:Platelet Factor 4